New daily shot could tame severe MG attacks
NCT ID NCT07215949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily injection called zilucoplan in 15 people hospitalized with severe myasthenia gravis (MG) flare-ups. The goal is to see if the drug can quickly improve daily living activities, like breathing and swallowing, within two weeks. Participants receive the injections for 12 weeks, and researchers track their progress for about 18 weeks total.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zilucoplan (a drug given as daily injections under the skin)
What this could lead to
If it works, this could provide a new treatment option for severe myasthenia gravis flare-ups, helping people recover faster and avoid prolonged hospital stays.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The drug may not improve symptoms significantly, and daily injections can be inconvenient or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact